ATE447621T1 - Verfahren zur bestimmung antiviraler wirkstoff suszeptibilität und resistenz sowie antivirales wirkstoff-screening - Google Patents

Verfahren zur bestimmung antiviraler wirkstoff suszeptibilität und resistenz sowie antivirales wirkstoff-screening

Info

Publication number
ATE447621T1
ATE447621T1 AT01117002T AT01117002T ATE447621T1 AT E447621 T1 ATE447621 T1 AT E447621T1 AT 01117002 T AT01117002 T AT 01117002T AT 01117002 T AT01117002 T AT 01117002T AT E447621 T1 ATE447621 T1 AT E447621T1
Authority
AT
Austria
Prior art keywords
antiviral active
resistance
determining
screening
active substance
Prior art date
Application number
AT01117002T
Other languages
German (de)
English (en)
Inventor
Daniel J Capon
Christos Petropoulous
Original Assignee
Monogram Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monogram Biosciences Inc filed Critical Monogram Biosciences Inc
Application granted granted Critical
Publication of ATE447621T1 publication Critical patent/ATE447621T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01117002T 1996-01-29 1997-01-29 Verfahren zur bestimmung antiviraler wirkstoff suszeptibilität und resistenz sowie antivirales wirkstoff-screening ATE447621T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59300996A 1996-01-29 1996-01-29

Publications (1)

Publication Number Publication Date
ATE447621T1 true ATE447621T1 (de) 2009-11-15

Family

ID=24372979

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01117002T ATE447621T1 (de) 1996-01-29 1997-01-29 Verfahren zur bestimmung antiviraler wirkstoff suszeptibilität und resistenz sowie antivirales wirkstoff-screening

Country Status (18)

Country Link
EP (2) EP1170380B1 (enExample)
JP (1) JP4183749B2 (enExample)
KR (1) KR100537153B1 (enExample)
CN (1) CN1263867C (enExample)
AP (1) AP9801360A0 (enExample)
AT (1) ATE447621T1 (enExample)
AU (1) AU732255B2 (enExample)
CA (1) CA2216126C (enExample)
DE (2) DE69739645D1 (enExample)
EA (1) EA005426B1 (enExample)
ES (1) ES2175355T3 (enExample)
HU (1) HUP9900388A3 (enExample)
IL (1) IL125464A (enExample)
NO (1) NO983421L (enExample)
NZ (1) NZ331376A (enExample)
PL (1) PL328068A1 (enExample)
RO (1) RO118887B1 (enExample)
WO (1) WO1997027319A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0656887B1 (en) 1992-08-25 1998-10-28 G.D. Searle & Co. Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
KR100495690B1 (ko) 1996-01-26 2005-11-08 비르코 비브이비에이 인체 hiv 계통의 표현형적 약제 감수성에 기초한 하나 이상의 최적한 hiv 저해제를 선발하는 방법
US6242187B1 (en) 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
JP2001512036A (ja) * 1997-07-30 2001-08-21 バイアラジック・インコーポレーテッド 抗ウイルス薬剤感受性および耐性を測定するための組成物および方法、並びに抗ウイルス薬剤をスクリーニングするための組成物および方法
WO1999051776A1 (en) * 1998-04-07 1999-10-14 Southern Research Institute High-throughput method for screening for antiviral activity
AU772511B2 (en) * 1998-05-26 2004-04-29 Virologic, Inc. Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy
US7037644B1 (en) 1998-05-26 2006-05-02 Virologic, Inc. Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
DE69924118T2 (de) * 1998-06-19 2005-12-22 The Government of the United States of America, as represented by the Secretary Centers for Disease and Prevention, Office of Technology Verfahren und reagentiensatz zur erkennung von antiviralen wirkstoff resistenzen
US6787126B1 (en) 1998-06-19 2004-09-07 The United States Of America As Represented By The Department Of Health And Human Services Method and kit for detecting resistance to antiviral drugs
US20030148307A1 (en) 1998-06-19 2003-08-07 Department Of Health & Human Services, C/O Centers Of Disease Control And Prevention Method and kit for detecting resistance to antiviral drugs
EP1015642A4 (en) * 1998-06-24 2005-03-23 Virologic Inc Means and methods for monitoring nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
DE60022036T2 (de) 1999-05-28 2006-06-08 Virco N.V. Neue mutationsprofile der hiv-1 reverse transcriptase in verbindung mit phänotypischem medikamentresistenz
CA2422489A1 (en) * 2000-09-15 2002-03-21 Virologic, Inc. Non-nucleoside reverse transcriptase inhibitor as antiretroviral therapy
DE60137580D1 (de) 2000-10-20 2009-03-19 Virco Bvba Festlegen von kritischen biologischen werten zur voraussage einer therapieresistenz
AU2002226316B2 (en) 2000-10-20 2008-06-26 Virco Bvba Mutational profiles in HIV-1 reverse transcriptase correlated with phenotypic drug resistance
US7247439B1 (en) 2001-06-04 2007-07-24 Monogram Biosciences, Inc. Method of evaluating a patient antibody response to envelope proteins of a virus
US7097970B2 (en) 2001-06-04 2006-08-29 Monogram Biosciences, Inc. Methods of evaluating viral entry inhibitors using patient derived envelope protein constructs
CA2466497A1 (en) 2001-11-08 2003-05-15 Tibotec Pharmaceuticals Ltd. Protease assay for therapeutic drug monitoring
WO2004003223A2 (en) 2002-07-01 2004-01-08 Tibotec Pharmaceuticals Ltd. New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
EP1520247B1 (en) 2002-07-01 2009-05-27 Tibotec Pharmaceuticals Ltd. Mutational profiles in hiv-1 protease correlated with phenotypic drug resistance
DE20218008U1 (de) 2002-11-21 2003-03-06 FESTO AG & Co., 73734 Esslingen Anordnung von mehreren Handhabungsvorrichtungen
US8603736B2 (en) 2004-06-07 2013-12-10 Monogram Biosciences, Inc. Compositions and methods for determining resistance to inhibitors of virus entry using recombinant virus assays
WO2006089046A2 (en) 2005-02-18 2006-08-24 Monogram Biosciences, Inc. Methods and compositions for determining anti-hiv drug susceptibility and replication capacity of hiv
US8178291B2 (en) 2005-02-18 2012-05-15 Monogram Biosciences, Inc. Methods and compositions for determining hypersusceptibility of HIV-1 to non-nucleoside reverse transcriptase inhibitors
EP2458019A3 (en) 2005-05-27 2012-07-25 Monogram BioSciences, Inc. Methods and compositions for determining resistance of HIV-1 to protease inhibitors
WO2006133266A2 (en) 2005-06-06 2006-12-14 Monogram Biosciences, Inc. Methods for determining resistance or susceptibility to hiv entry inhibitors
US8071284B2 (en) 2005-06-06 2011-12-06 Monogram Biosciences, Inc. Methods and compositions for determining altered susceptibility of HIV-1 to anti-HIV drugs
WO2007146336A2 (en) 2006-06-13 2007-12-21 Monogram Biosciences, Inc. Molecular determinants associated with enhanced ability to enter cells expressing cxcr4
US8338101B2 (en) * 2007-01-23 2012-12-25 Virco Bvba Method for designing a drug regime for HIV-infected patients
US9581595B2 (en) 2007-02-26 2017-02-28 Laboratory Corporation Of America Holdings Compositions and methods for determining whether a subject would benefit from co-receptor inhibitor therapy
JPWO2018030534A1 (ja) * 2016-08-10 2019-06-13 国立研究開発法人理化学研究所 Ｂ型肝炎治療用組成物、及びｂ型肝炎ウイルスの複製活性の評価方法
RU2646472C1 (ru) * 2016-10-07 2018-03-05 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный медицинский университет имени академика Е.А. Вагнера" Министерства здравоохранения Российской Федерации Способ оценки эффективности терапии инфекции вызванной вирусом герпеса человека 6 типа у детей
CN110382009A (zh) * 2016-12-29 2019-10-25 富荣吉有限责任公司 Retro-HBV和Lenti-HBV的混合载体及构建体
CN109722465B (zh) * 2019-01-07 2022-02-01 福建省疾病预防控制中心(福建省健康教育促进中心、福建省卫生检验检测中心) 一种hiv耐药检测载体和构建方法
WO2021259345A1 (zh) * 2020-06-24 2021-12-30 厦门大学 靶向HBV cccDNA的药物筛选模型及方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0291893A1 (en) * 1987-05-19 1988-11-23 The Du Pont Merck Pharmaceutical Company Stable human cell lines expressing an indicator gene product under virus-specific genetic controls
EP0361749B1 (en) * 1988-09-27 1995-02-08 Dana Farber Cancer Institute A vector comprising a replication competent HIV-I provirus and a heterologous gene
HU209835B (en) * 1988-12-07 1994-11-28 Univ Osaka Res Found Method for producing of retrovirus protease, reverse transcriptase and integrase
EP0414475B1 (en) * 1989-08-25 1997-12-10 Chiron Corporation Methods for culturing HCV in B- or T-lymphocyte cell lines
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
FR2700169B1 (fr) * 1993-01-04 1995-03-24 Transgene Sa Nouveaux variants trans-dominants TAT du virus de l'immunodéficience humaine.
US5645982A (en) * 1993-08-19 1997-07-08 Systemix, Inc. Method for screening potential therapeutically effective antiviral agents
WO1995022622A1 (en) * 1994-02-18 1995-08-24 University Of Washington Methods and compositions for screening for anti-aids drugs
US5733543A (en) * 1994-04-29 1998-03-31 Nabel; Gary J. Introduction of HIV-protective genes into cells by particle-mediated gene transfer
AU2585395A (en) * 1994-05-09 1995-11-29 Chiron Corporation Retroviral vectors having a reduced recombination rate
US5837464A (en) * 1996-01-29 1998-11-17 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
JP2001512036A (ja) * 1997-07-30 2001-08-21 バイアラジック・インコーポレーテッド 抗ウイルス薬剤感受性および耐性を測定するための組成物および方法、並びに抗ウイルス薬剤をスクリーニングするための組成物および方法

Also Published As

Publication number Publication date
EA199800669A1 (ru) 1999-02-25
HUP9900388A3 (en) 2005-03-29
NO983421D0 (no) 1998-07-24
RO118887B1 (ro) 2003-12-30
IL125464A0 (en) 1999-03-12
AP9801360A0 (en) 1998-12-31
EA005426B1 (ru) 2005-02-24
HUP9900388A2 (hu) 1999-05-28
DE69739645D1 (de) 2009-12-17
JP2000503849A (ja) 2000-04-04
ES2175355T3 (es) 2002-11-16
CA2216126C (en) 2009-03-31
EP1170380A3 (en) 2003-05-02
PL328068A1 (en) 1999-01-04
AU732255B2 (en) 2001-04-12
NO983421L (no) 1998-09-25
CN1213407A (zh) 1999-04-07
KR100537153B1 (ko) 2006-12-15
AU1952897A (en) 1997-08-20
EP0852626A1 (en) 1998-07-15
EP1170380A2 (en) 2002-01-09
EP0852626A4 (en) 1999-08-25
EP1170380B1 (en) 2009-11-04
JP4183749B2 (ja) 2008-11-19
CA2216126A1 (en) 1997-07-31
NZ331376A (en) 2000-03-27
DE69711584T2 (de) 2002-11-07
CN1263867C (zh) 2006-07-12
DE69711584D1 (de) 2002-05-08
IL125464A (en) 2007-12-03
KR19990082129A (ko) 1999-11-15
WO1997027319A1 (en) 1997-07-31
EP0852626B1 (en) 2002-04-03

Similar Documents

Publication Publication Date Title
ATE447621T1 (de) Verfahren zur bestimmung antiviraler wirkstoff suszeptibilität und resistenz sowie antivirales wirkstoff-screening
DE69628999D1 (de) ATP-Eliminator und Verfahren zur Bestimmung von biologischen Zellen
DE69534399D1 (de) Verfahren und Gerät zur Bestimmung von Merkmalpunkten
DE60035733D1 (de) Einrichtung und Verfahren zur quantitativen Bestimmung der Aenderung in einem Elektrokardiogrammsignal
DE69518303D1 (de) Verfahren zur Detektierung menschlicher Anwesenheit und System
DE69331339D1 (de) Gerät und verfahren zur bestimmung der blutgerinnungszeit
DE69700253D1 (de) Verfahren und Vorrichtung zur Bestimmung der Konzentration eines Bestandteils
DE69707325D1 (de) Bilderzeugungsmaterial und Verfahren
DE69739854D1 (de) System und verfahren zur bestimmung von spannungen
DE69836558D1 (de) Verfahren und vorrichtung zur bestimmung einer konzentration
DE69636398D1 (de) Blutbehandlungssystem und Verfahren zur Gewinnung von mononuklearen Zellen
ATE225039T1 (de) Volumenunabhängiger diagnostischer testträger und verfahren zur bestimmung von analyten mit dessen hilfe
DE59814198D1 (de) Verfahren und Messgerät zur Bestimmung des Blutdrucks
DE59510184D1 (de) Einrichtung und verfahren zur hautuntersuchung
DE69517955D1 (de) Verfahren und gerät zur nichtinvasiven vorhersage von hämatokrit
DE69816789D1 (de) Verfahren und system zur gestengesteuerten optionsauswahl
DE69510965D1 (de) Verfahren zur Bestimmung der Position und zugehörige Vorrichtung
DE69518794D1 (de) EMI-Filter und Verfahren zur Bestimmung desselben
DE69828571D1 (de) Blutfiltersatz und zugehöriges Verfahren zur Gewinnung von Blutkomponenten
DE69712937D1 (de) Verfahren zur Bestimmung einer Kalibrierungskurve und Analyseverfahren und diesen Verfahren verwendendes Gerät.
DE69632960D1 (de) System und verfahren zur kompostierung
DE69700087D1 (de) Gerät und Verfahren zur Signalanalyse
DE59710226D1 (de) Einrichtung und verfahren zur leckageerkennung
DE69822830D1 (de) Verfahren und vorrichtung zur bestimmung und charakterisierung von teilchen
DE69510174D1 (de) Verfahren und Reagenz zur Bestimmung von menschlichen Störungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties